Bausch Health Companies Inc.

BHC
About the company

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health.

Country: CanadaPrice: $8.35Market Cap: $3.1B

Investment snapshot

6%positive consensus
Scored 1d ago

Positive

1

BUY / PASS

Neutral / negative

4 / 11

NEUTRAL / FAIL

Median fair value

$30.87

+269.7% vs price

Models with upside

5 / 17

Positive margin of safety

Strongest signal

All 10 investors pass BHC's cash flow

Key risk

No clean pass — all 12 investors flag at least one debt & leverage criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #711 (Top 23%)NEUTRALFAILFAILFAILFAILFAILNEUTRALFAILPASSNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/A+73.0%N/A+72.8%N/AN/A+72.7%+78.7%N/AN/A+85.3%N/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-10-29

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-10-29

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-10-29

Score computed: 2026-11-14

TTM ended 2026-09-30

Latest source filing: 2026-10-29

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-19

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-10-29

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-10-29

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-02-19

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-10-29

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Qualitative assessment

Latest source filing: 2026-10-29

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-10-29

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30

Latest source filing: 2026-10-29

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-02-19

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-10-29

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-10-29

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-10-29

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-10-29

Score computed: 2026-11-14

Where It Passes

  • Cash Flow100% pass✓ 12▾

    All 10 investors pass BHC's cash flow

    Free Cash Flow Proxy$968.0M
    ✓BuffettPositive and growing
    FCF Positive and Growing$1.9B
    ✓LynchPositive and growing
    Operating Cash Flow$1.4B
    ✓PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=5.31%, ROA=0.60%
    ✓PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)2.2x
    ✓Dreman< 8x
    P/E or FCF YieldP/E=19.9x, FCF Yield=32.1%
    ✓PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive17/18 years FCF positive
    ✓MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap60.3%
    ✓Ackman>= 4%
    Price / FCF per Share3.1x
    ✓Ackman<= 25
    Positive Operating Cash Flow frequency17/18 years positive
    ✓SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$1.9B
    ✓Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization+59.68%; #87/4519 (top 1.9%)
    ✓OshaughnessyTop 10% of eligible cross-section
  • Valuation models100% pass✓ 5▾

    BHC undervalued: all 5 models price fair value above $8.35 (median $30.87)

    Buffett fair value$30.87
    ✓Buffett+73.0% margin vs $8.35
    Greenblatt fair value$30.71
    ✓Greenblatt+72.8% margin vs $8.35
    Munger fair value$30.54
    ✓Munger+72.7% margin vs $8.35
    Pabrai fair value$39.18
    ✓Pabrai+78.7% margin vs $8.35
    Ackman fair value$56.77
    ✓Ackman+85.3% margin vs $8.35

Where It Falls Short

  • Debt & Leverage0% pass✓ 2✗ 13▾

    No clean pass — all 12 investors flag at least one debt & leverage criterion

    LT Debt vs Net Current AssetsLT Debt $19.8B vs NCA $2.7B
    ✗GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest CoverageD/E: N/A (negative equity), IC: 0.8x
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / EquityN/A (negative equity)
    ✗Lynch< 0.33
    Cash - Long-term Debt$-17.3B
    ✗LynchPositive preferred
    LT Debt / Total Assets Change71.42% -> 78.10%
    ✗PiotroskiDecreased YoY
    Current Assets / Current Liabilities1.56
    ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity
    ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
    Debt LevelsN/A (non-positive equity)
    ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDAIC=0.8x, D/EBITDA=8.6x
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity
    ✗Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)
    ✗AsnessTop 30% of eligible cross-section
  • Profitability6% pass✓ 8✗ 27▾

    15 of 16 flag BHC's profitability — Graham, Buffett, Lynch +12 more

    Positive EPS (10 years)6/18 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)7/18 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)-92.0%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)17.7% (latest)
    ✗BuffettStable or rising over 10 years
    Free Cash Flow Proxy$968.0M
    ✓BuffettPositive and growing
    Earnings Variance (10-yr CoV)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROEN/A (negative equity)
    ✗Lynch> 15%
    EBIT / Enterprise Value5.9%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=5.9%, ROC=39.6%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets0.60%
    ✓PiotroskiROA > 0
    ROA Change YoY-0.17% -> 0.60% (delta: +0.77%)
    ✓PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=5.31%, ROA=0.60%
    ✓PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY
    ✗PiotroskiImproved YoY
    Pre-Tax Income / Revenue-3.2%
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity
    ✗Dreman> 12%
    Margin of SafetyP/E=19.9x
    ✗PabraiP/B < 1.5 or P/E < 15
    Return on Equity-141.5% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency7/18 years positive
    ✓MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue11.2%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity
    ✗Ackman>= 15%
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend11.0% (2023) -> 17.7% (2025)
    ✓TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendrevenue up, operating margin 11.0% -> 17.7%
    ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization-26.91%; #4739/6340 (top 74.7%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets
    ✗AsnessTop 30% of eligible cross-section
    Net income / positive book equity
    ✗AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.0138; #1070/5884 (top 18.2%)
    ✓AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR36.8% over 3 years
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years2/10 years positive
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Verdicts8% pass✓ 1✗ 12▾

    Split decision: 11 FAIL · 4 NEUTRAL · 1 PASS

    Overall verdict
    ✗GrahamFAIL (1/9)✗BuffettFAIL (1/9)✗LynchFAIL (2/7)✗GreenblattRank #711•PiotroskiNEUTRAL (F-Score 6)✗DremanFAIL (3/11)✗MungerFAIL (1/4)✗PabraiFAIL (1/3)✗AkreFAIL (1/6)✗MarksFAIL (2/5)•AckmanNEUTRAL (6/9)✗TempletonFAIL (2/8)✓SleepPASS (3/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (2/6)✗SchlossFAIL (1/7)•OshaughnessyNEUTRAL (Not ranked)
  • Valuation23% pass✓ 5✗ 23▾

    10 of 13 flag BHC's valuation — Graham, Lynch, Greenblatt +7 more

    Price / 3-yr avg EPS
    ✗Graham<= 15x
    Price-to-Book Ratio
    ✗Graham<= 1.5x
    P/E x P/B
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value5.9%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=5.9%, ROC=39.6%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS19.9x
    ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)2.2x
    ✓Dreman< 8x
    Price / Book Value per ShareN/A (negative BVPS)
    ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Valuation ReasonablenessP/E=19.9x, OE Yield=31.3%
    ✓MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldP/E=19.9x, FCF Yield=32.1%
    ✓PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/E=19.9x
    ✗MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Price / FCF per Share3.1x
    ✓Ackman<= 25
    Price vs. Trailing Low184% of trailing low ($4.53)
    ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization-26.91%; #4739/6340 (top 74.7%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization-0.4249; #5928/6449 (top 91.9%)
    ✗AsnessTop 30% of eligible cross-section
    Price / Diluted EPS19.9x
    ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per ShareN/A (non-positive TBVPS)
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change-199.4%
    ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+3.5560; #702/5247 (top 13.4%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization+59.68%; #87/4519 (top 1.9%)
    ✓OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date+49.11%; #669/6202 (top 10.8%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Growth25% pass✓ 5✗ 8▾

    6 of 8 flag BHC's growth — Graham, Lynch, Dreman +3 more

    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthInv: -0.4% vs Rev: 10.8%
    ✓LynchInventory growth < Revenue growth
    EPS Growth Direction
    ✗DremanPositive over recent years
    EPS CAGR
    ✗Dreman> 5% annualized
    Positive Net Income Frequency7/18 years positive
    ✓MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth7.8%
    ✓Ackman>= 5%
    Positive EPS Growth Frequency3/5 years with positive EPS growth
    ✓AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendrevenue up, operating margin 11.0% -> 17.7%
    ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR5.0%
    ✗SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR36.8% over 3 years
    ✗Neff7%-20% annualized
  • Efficiency38% pass✓ 4✗ 7▾

    5 of 8 flag BHC's efficiency — Graham, Buffett, Munger +2 more

    Current Ratio1.56
    ✗Graham>= 2.0
    ROIC (3-5 yr avg)4.2%
    ✗Buffett> 10%
    ROIC - WACC-5.8%
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)39.6%
    ✓Greenblatt> 25%
    Current Ratio Change YoY0.86 -> 1.47
    ✓PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY0.36x -> 0.39x
    ✓PiotroskiImproved YoY
    Current Assets / Current Liabilities1.56
    ✓Dreman> 1.5
    Return on Invested Capital5.1%
    ✗Munger> 15%
    ROIC (high and growing)FY2023: ROIC=3.6%; FY2024: ROIC=6.0%; FY2025: ROIC=7.1%
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROIC7.1% (RR=100% x ROIC=7.1%)
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)0/5 years above 12% (latest 7.1%)
    ✗SleepROIC > 12% in a majority of years

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Pharmaceutical Products
SIC Sector: Chemicals & Pharmaceuticals
Size: Mid Cap($3.1B)
Revenue: $10.3B+6.7% YoY
Net Income: $157.0M+441.3% YoY

Financial Snapshot

Operating Margin17.7%
Return on Equity-28.3%
Debt / Equity-37.58
Current Ratio1.47
EPS (Diluted)$0.42
Shares Retired−0.7% / −1.4% 2y

Similar Companies

MRKMerck & Co., Inc.
$364.3B
ABTABBOTT LABORATORIES
$188.0B
BMYBRISTOL MYERS SQUIBB CO
$129.7B
TECHBIO-TECHNE Corp
$11.4B

Shareholder Return

Fiscal 2025

Issued 0.7% of shares last year, 1.4% issued over two.

Buybacks
—
Dividends
—

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricTTM · 2026-09-30

2025-10-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: revenue, net income, operating income, ebit, pre tax income, interest expense, operating cash flow, depreciation amortization, capex.

Q3 FY 2026

2026-07-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

Q2 FY 2026

2026-04-01 – 2026-06-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

Q1 FY 2026

2026-01-01 – 2026-03-31

Sources
FY 2025
Sources
  • 10-K · 2026-02-19
FY 2024
Sources
  • 10-K · 2025-02-20
FY 2023
Sources
  • 10-K · 2024-02-22
FY 2022
Sources
  • 10-K · 2023-02-23
FY 2021
Sources
  • 10-K · 2022-02-23
Market Cap$3.1Bcurrent------$2.1Best.$2.7Best.$2.9Best.$2.8Best.$8.8Best.
Revenue$11.1B↑11%$2.9B↑10%$2.9B↑13%$2.5B↑12%$10.3B↑7%$9.6B↑10%$8.8B↑8%$8.1B↓4%$8.4B
Operating Income$1.2B↓34%$983.0M↑59%$740.0M↑67%-$950.0M↓444%$1.8B↑17%$1.5B↑61%$963.0M↑112%$454.0M↑1%$450.0M
Net Income-$841.0M↓332%$436.0M↑144%$258.0M↑74%-$1.4B↓2353%$157.0M↑441%-$46.0M↑92%-$592.0M↓163%-$225.0M↑76%-$948.0M
EPS (Diluted)--$1.15↑140%$0.68↑70%$-3.82↓2287%$0.42↑423%$-0.13↑92%$-1.62↓161%$-0.62↑77%$-2.64
Gross Margin—————————
Operating Margin11.2%↓41%33.4%↑45%25.9%↑48%-37.6%↓408%17.7%↑10%16.1%↑46%11.0%↑97%5.6%↑5%5.3%
ROE63.3%↑199%———-28.3%↓888%3.6%↓94%57.9%↑78%32.5%↓96%894.3%
Total Debt$20.6B↓2%$20.6B↓2%$20.7B↓5%$20.8B↓3%$20.8B↓4%$21.6B↓3%$22.4B↑8%$20.8B↓8%$22.7B
Shareholders' Equity-$1.3B↓135%-$1.3B↓135%-$1.8B↓132%-$2.1B↓74%-$554.0M↑57%-$1.3B↓25%-$1.0B↓48%-$692.0M↓553%-$106.0M
Current Ratio1.56↑20%1.56↑20%1.44↑10%1.32↓2%1.47↑72%0.86↓34%1.30↑21%1.081.08
Debt / Equity-15.54↑58%-15.54↑58%-11.71↑59%-10.08↑45%-37.58↓122%-16.90↑23%-21.91↑27%-30.01↑86%-213.72
Operating Cash Flow$2.2B↑47%$814.0M↑101%$670.0M↑132%$230.0M↑9%$1.4B↓12%$1.6B↑55%$1.0B↑242%-$728.0M↓151%$1.4B
Free Cash Flow$1.9B↑70%$748.0M↑138%$593.0M↑212%$121.0M↑26%$1.0B↓20%$1.3B↑54%$817.0M↑186%-$946.0M↓182%$1.2B

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Pharmaceutical Products

BHC vs Peers — Financial Grading

Revenue$10.3BMedian
Net Income$157.0MMedian
ROE-28.3%Bottom 25%
D/E-37.58Top 25%
Op. Margin17.7%Median
Curr. Ratio1.47Bottom 25%
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
Merck & Co., Inc.MRK$364.3B$147.76$65.0B$18.3B34.7%0.94—1.542/95/94/70/3F-Score 41/11
ABBOTT LABORATORIESABT$188.0B$108.52$44.3B$6.5B12.5%0.2518.2%1.583/94/92/71/3F-Score 53/11
BRISTOL MYERS SQUIBB COBMY$129.7B$63.43$48.2B$7.1B38.2%2.4419.4%1.262/91/93/71/3F-Score 85/11
BIO-TECHNE CorpTECH$11.4B$72.80$1.2B$73.4M3.8%—8.4%3.464/93/93/70/3F-Score 54/11
REPLIGEN CORPRGEN$10.7B$167.79$738.3M$48.9M2.3%0.267.5%8.373/92/93/70/3F-Score 75/11
IONIS PHARMACEUTICALS INCIONS$4.8B$29.06$943.7M$381.4M-78.0%3.60-40.4%3.833/91/91/70/3F-Score 43/11
NEOGEN CORPNEOG$2.5B$11.23$870.4M$7.9M-0.4%0.76-2.5%3.823/91/92/70/3F-Score 64/11
Pharvaris N.V.PHVS$2.4B$33.36—$206.4M-64.8%0.00——0/90/92/70/3F-Score 22/11